PuSH - Publikationsserver des Helmholtz Zentrums München

175 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Chen, B.R.* et al.: A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis In AF10-rearranged AML. Blood, DOI: 10.1182/blood.2020009023 (2021)
2.
Chen, J.* et al.: ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia. Blood, DOI: 10.1182/blood.2020009960 (2021)
3.
Deng, Y.* et al.: CD27 is required for protective lytic EBV antigen specific CD8+ T cell expansion. Blood, DOI: 10.1182/blood.2020009482 (2021)
4.
Frey, L.* et al.: Mammalian VPS45 orchestrates trafficking through the endosomal system. Blood 137, 1932-1944 (2021)
5.
Sormendi, S.* et al.: HIF2α is a direct regulator of neutrophil motility. Blood, DOI: 10.1182/blood.2020007505 (2021)
6.
Stenger, D.* et al.: Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood 136, 1407-1418 (2020)
7.
Bahrami, E. et al.: A CRISPR/Cas9 library screen in patients’ leukemia cells in vivo. Blood 134, 1:3945 (2019)
8.
Garg, S.* et al.: Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. Blood 134, 263-276 (2019)
9.
Sperling, S. et al.: Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. Blood 133, 2597-2609 (2019)
10.
Burchert, A.* et al.: Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: Results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood 132 (2018)
11.
Danisch, S.* ; Slabik, C.* ; Zeidler, R. ; Ganser, A.* & Stripecke, R.*: CAR-T cells targeting gp350 recognize immortalized cells latently infected with EBV. Blood 132 (2018)
12.
De Braekeleer, E.* et al.: The nucleotide kinase nadk is required for ROS detoxification and constitutes a metabolic vulnerability of NOTCH1-driven T-ALL. Blood 132 (2018)
13.
Ebinger, S. ; Vick, B. ; Spiekermann, K.* & Jeremias, I.: Long-term dormant cells in acute myeloid leukemia patient-derived xenografts display reversible treatment resistance, but are not enriched for leukemia-initiating cells. Blood 132 (2018)
14.
Hermann, M.* et al.: Bifunctional PD-1 x alpha CD3 x alpha CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 132, 2484-2494 (2018)
15.
Hermann, M.* et al.: Development of a bifunctional checkpoint inhibitory T cell engager (CiTE) to reverse adaptive immune escape in AML. Blood 132 (2018)
16.
Kuhn, L. et al.: The non-canonical NF-kappaB Signaling Pathway Contributes to the Expansion and Lymphomagenesis of CD40-activated B Cells. Blood 132 (2018)
17.
Kyncl, M.* et al.: Data driven computational modeling of hematopoiesis in myelodysplastic syndromes unveils differences in hematopoietic stem cell kinetics compared to age-matched healthy controls. Blood 132 (2018)
18.
Lenk, L.* et al.: CD79a is associated with central nervous system infiltration of pediatric B-cell precursor acute lymphoblastic leukemia. Blood 132 (2018)
19.
Passerini, V.* et al.: PARP14 is a novel therapeutic target in STAT6 mutant follicular lymphoma. Blood 132 (2018)
20.
Stief, S.M.* et al.: Loss of KDM6A confers drug resistance in acute myeloid leukemia. Blood 132 (2018)